Le Lézard
Classified in: Health
Subjects: RCL, PSF, CFG

Advisory - Martin Clinic Liquid Vitamin D recalled due to incorrect dosing and missing safety information on the label


OTTAWA, ON, July 6, 2021 /CNW/ -

Summary

Issue

Pur Naturals is recalling all lots of Martin Clinic Liquid Vitamin D due to incorrect dosing instructions on the label that could lead to taking too much vitamin D, which may pose serious health risks. The label is also missing important warnings, including that the product is not for use by children under 12 years of age, and to consult a health care professional if taking blood thinners.

The product is sold by Martin Clinic and Nutrition Centre online, and at their clinic and supplement store, which is located in Sudbury, Ontario.

The dosing instructions on the label ("1 or more drops per day or as recommended by your health care professional") suggest that more than 1 drop can be taken per day, which can lead to taking dangerously high amounts. The maximum allowable dose for this product is 1 drop per day.

Signs of too much vitamin D include weakness, fatigue, drowsiness, headache, lack of appetite, dry mouth, metallic taste, nausea, vomiting, vertigo, ringing in the ears, lack of coordination, and muscle weakness. Pregnant women in particular should not take vitamin D exceeding the daily tolerable upper intake level for adults (4,000 IU) which includes food intake. High levels of vitamin D taken during pregnancy can potentially lead to high calcium levels in the pregnant woman, which can be associated with risks to the newborn.

In addition, the product label is missing the warning statement "Consult a health care professional prior to use if you are taking blood thinners." The product contains vitamin K2, which is a form of vitamin K. There is no tolerable upper intake level for vitamin K; however, vitamin K may interfere with blood thinners. People taking blood thinners need to maintain a consistent intake of vitamin K from food and supplements because sudden changes in vitamin K intake can increase or decrease the anticoagulant (blood thinning) effect.

Affected products

What you should do

Également disponible en français

SOURCE Health Canada


These press releases may also interest you

at 06:03
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...

at 06:00
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...

at 05:30
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...



News published on and distributed by: